{
    "pmcid": "10384293",
    "summary": "The paper titled \"SARS-CoV-2 Spike Protein Is Capable of Inducing Cell\u2013Cell Fusions Independent from Its Receptor ACE2 and This Activity Can Be Impaired by Furin Inhibitors or a Subset of Monoclonal Antibodies\" provides a comprehensive analysis of the SARS-CoV-2 spike protein's ability to mediate cell-cell fusion independently of its known receptor, ACE2. This study has significant implications for the design of SARS-CoV-2 nanobody binders, particularly in understanding the spike protein's structure-function relationship and its role in viral pathogenicity.\n\n### Key Insights on SARS-CoV-2 Spike Protein:\n\n1. **ACE2-Independent Fusion Activity**:\n   - The SARS-CoV-2 spike protein can induce cell-cell fusion without the presence of ACE2, a feature not observed in the SARS-CoV-1 spike protein.\n   - This receptor-independent fusion is dependent on the proteolytic cleavage of the spike protein by furin, while TMPRSS2 is not required.\n\n2. **Proteolytic Cleavage Sites**:\n   - The spike protein requires cleavage at both the S1/S2 and S2\u2032 sites for its fusogenic activity.\n   - Furin cleavage is critical for this process, and the inhibition of furin with CMK significantly reduces fusion activity.\n\n3. **Variant-Specific Fusogenicity**:\n   - Variants of concern (VOCs) exhibit different levels of fusogenicity. The Delta variant shows high fusion activity, while the Omicron variant shows minimal activity.\n   - The differences in fusogenicity among variants are not solely dependent on the furin cleavage site but also on other regions, particularly around residue 655.\n\n4. **Role of Specific Amino Acids**:\n   - Amino acids 652-1273 are crucial for ACE2-independent fusion activity.\n   - Residue 655, in particular, plays a significant role in regulating this fusion activity, with mutations at this site affecting the fusogenic potential.\n\n5. **Antibody Inhibition**:\n   - Monoclonal antibodies (mAbs) targeting the N-terminal domain (NTD) of the spike protein can inhibit ACE2-independent fusion, while those targeting the receptor-binding domain (RBD) do not.\n   - This suggests that the NTD is a critical target for therapeutic antibodies aimed at preventing cell-cell fusion.\n\n### Implications for Nanobody Design:\n\n- **Targeting the NTD**: Given the ability of NTD-targeting antibodies to block ACE2-independent fusion, designing nanobodies that bind to the NTD could be a promising strategy for therapeutic intervention.\n- **Furin Cleavage Inhibition**: Nanobodies or small molecules that inhibit furin cleavage could effectively reduce the spike protein's fusogenic activity, offering another therapeutic avenue.\n- **Variant-Specific Strategies**: Understanding the structural differences in spike proteins across variants can guide the design of nanobodies that are effective against multiple variants, especially those with high fusogenic potential like Delta.\n- **Focus on Conserved Regions**: Targeting conserved regions within the spike protein, particularly those involved in fusion, could lead to broad-spectrum nanobodies effective against various SARS-CoV-2 variants.\n\nThis study underscores the complexity of the spike protein's role in SARS-CoV-2 pathogenicity and highlights the potential for developing novel therapeutic strategies targeting its fusogenic properties. The insights gained from this research can inform the rational design of nanobodies and other therapeutic agents aimed at mitigating the spread and impact of SARS-CoV-2.",
    "title": "SARS-CoV-2 Spike Protein Is Capable of Inducing Cell\u2013Cell Fusions Independent from Its Receptor ACE2 and This Activity Can Be Impaired by Furin Inhibitors or a Subset of Monoclonal Antibodies"
}